NCT01356940View on ClinicalTrials.gov

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Multiple Sclerosis
Interventions
DRUG

dalfampridine ER

dalfampridine ER 10mg bid for 4 weeks

DRUG

placebo

identical placebo tablet administered bid for four weeks

Trial Locations (1)

98034

MS Center at Evergreen, Kirkland

Sponsors

Collaborators (1)

Acorda Therapeutics
All Listed Sponsors
collaborator

Acorda Therapeutics

INDUSTRY

lead

Brown, Theodore R., M.D., MPH

INDIV